The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017–2018 cycle
Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used t...
Saved in:
| Published in | BMC gastroenterology Vol. 24; no. 1; pp. 218 - 7 |
|---|---|
| Main Authors | , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
BioMed Central
08.07.2024
BioMed Central Ltd BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1471-230X 1471-230X |
| DOI | 10.1186/s12876-024-03295-8 |
Cover
Loading…
| Abstract | Background
Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC.
Methods
Participants aged ≥ 18 years with VCTE exam in the NHANES 2017–2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45–0.67 and AGILE 4 of 0.25–0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out.
Results
1244 subjects were included in the final analysis. The Median age was 53 (51.4–54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans.
Conclusion
Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. |
|---|---|
| AbstractList | Abstract Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC. Methods Participants aged ≥ 18 years with VCTE exam in the NHANES 2017–2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45–0.67 and AGILE 4 of 0.25–0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out. Results 1244 subjects were included in the final analysis. The Median age was 53 (51.4–54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans. Conclusion Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC. Methods Participants aged [greater than or equal to] 18 years with VCTE exam in the NHANES 2017-2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of [greater than or equal to] 0.68 and AGILE 4 score of [greater than or equal to] 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45-0.67 and AGILE 4 of 0.25-0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out. Results 1244 subjects were included in the final analysis. The Median age was 53 (51.4-54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans. Conclusion Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. Keywords: MASLD, AGILE, Elastography, Cirrhosis, Advanced fibrosis, NHANES Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC. Participants aged ≥ 18 years with VCTE exam in the NHANES 2017-2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45-0.67 and AGILE 4 of 0.25-0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out. 1244 subjects were included in the final analysis. The Median age was 53 (51.4-54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans. Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC.BACKGROUNDStudies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC.Participants aged ≥ 18 years with VCTE exam in the NHANES 2017-2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45-0.67 and AGILE 4 of 0.25-0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out.METHODSParticipants aged ≥ 18 years with VCTE exam in the NHANES 2017-2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45-0.67 and AGILE 4 of 0.25-0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out.1244 subjects were included in the final analysis. The Median age was 53 (51.4-54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans.RESULTS1244 subjects were included in the final analysis. The Median age was 53 (51.4-54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans.Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD.CONCLUSIONOur results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC. Methods Participants aged ≥ 18 years with VCTE exam in the NHANES 2017–2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45–0.67 and AGILE 4 of 0.25–0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out. Results 1244 subjects were included in the final analysis. The Median age was 53 (51.4–54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans. Conclusion Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC. 1244 subjects were included in the final analysis. The Median age was 53 (51.4-54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans. Our results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. BackgroundStudies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which overestimates prevalence. AGILE3 + and 4 scores were developed to increase the PPV of both; respectively. In this study, we used these scores to assess the prevalence of AF and MC.MethodsParticipants aged ≥ 18 years with VCTE exam in the NHANES 2017–2018 cycle were included. We excluded pregnant women, patients with excessive alcohol intake, hepatitis B/C, and ALT or AST > 500 IU/L. MASLD was defined with CAP score > 248 dB/m. MASLD subjects with AGILE 3 + score of ≥ 0.68 and AGILE 4 score of ≥ 0.57 were considered to have advanced fibrosis and cirrhosis; respectively. AGILE 3 + of 0.45–0.67 and AGILE 4 of 0.25–0.57 were grey zone, whereas AGILE 3 + < 0.45 and AGILE 4 < 0.25 were considered a rule-out.Results1244 subjects were included in the final analysis. The Median age was 53 (51.4–54.6) years, 55.6% were male, median BMI was 33.8 kg/m2 and 41.1% had T2DM. Based on AGILE 3+, 80.3% of the MASLD population were at low risk for AF and 11.5% were in grey zone. The prevalence of AF due to MASLD was 8.1% corresponding to 4.5 million Americans. Based on AGILE 4 score, 96.5% of the MASLD population were at low risk for cirrhosis and 2.4% were in the grey zone. The prevalence of MASLD-cirrhosis was 1.1% corresponding to 610,000 Americans.ConclusionOur results suggest that approximately 4.5 million people in the U.S. have AF and 0.6 million have cirrhosis due to MASLD. |
| ArticleNumber | 218 |
| Audience | Academic |
| Author | Polanco, Prido Asaad, Imad Kumar, Prabhat Leff, Phillip Payne, Julia Y. Noureddin, Mazen Almomani, Ashraf Alkhouri, Naim Le, Phuc |
| Author_xml | – sequence: 1 givenname: Naim surname: Alkhouri fullname: Alkhouri, Naim email: nalkhouri@azliver.com organization: Hepatology and Liver Transplantation, Arizona Liver Health – sequence: 2 givenname: Ashraf surname: Almomani fullname: Almomani, Ashraf organization: Cleveland Clinic Florida – sequence: 3 givenname: Phuc surname: Le fullname: Le, Phuc organization: Cleveland Clinic Florida – sequence: 4 givenname: Julia Y. surname: Payne fullname: Payne, Julia Y. organization: Cleveland Clinic Florida – sequence: 5 givenname: Imad surname: Asaad fullname: Asaad, Imad organization: Cleveland Clinic Florida – sequence: 6 givenname: Prido surname: Polanco fullname: Polanco, Prido organization: Hepatology and Liver Transplantation, Arizona Liver Health – sequence: 7 givenname: Phillip surname: Leff fullname: Leff, Phillip organization: Hepatology and Liver Transplantation, Arizona Liver Health – sequence: 8 givenname: Prabhat surname: Kumar fullname: Kumar, Prabhat organization: Cleveland Clinic Foundation – sequence: 9 givenname: Mazen surname: Noureddin fullname: Noureddin, Mazen organization: Cedar Sinai Medical Center |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38977950$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9k81u1DAQxyNURD_gBTggS1yKUIo_NonTC1qV0lZayqGtxM1ynPHWVTZe7GSl5dQrZ96wL8ArMNktpa1QFUX-yP__m8xoZjvZaH0LSfKa0T3GZP4hMi6LPKV8lFLByyyVz5ItNipYygX9tnFvv5lsx3hFKSskFy-STSHLoigzupX8Pr8EMg-w0A20Boi3ZAadrnzjDKmX0fat6ZxvUx2jN053UJPYge58h4LGLSCQ2kXQEcjul_HZ5NO7NECz0ul6oZFZE-uq4KOLRLc1MS6Ey9XJtaTD6BetG9RnHZoimft5j3YMSfrONe6Ha6dkfHQyOSTi5vrne3wHyvpmRKLxAeI-knWzHKCYwAA9PR6fHp4RjinfXP_CRRKzNA28TJ5b3UR4dbvuJBefD88PjtPJ16OTg_EkNTmVXWppVhVclMyAHlGwQ6FtWTNjhS1KiofcCCsNY6IStMbia8izuspNZsBaI3aSkzW39vpKzYOb6bBUXju1uvBhqnTAEjagBFQYReqirPQIKFQaGGS8xjOTVVUi6-OaNe-rGdQG2i7o5gH04ZfWXaqpXyjGOC95zpGwe0sI_nsPsVMzFw00jW7B91EJWhSsyFGL0rePpFe-D1jdlapkkpeY9J1qin2jXGs9BjYDVI0lpTkfZWJg7f1HhU8NM2ewma3D-weGN_czvUvxb7-igK8FBhsqBrB3EkbVMBRqPRQKh0KthkJJNMlHJuO6VYvh77jmaatYWyPGaacQ_lXjCdcfAsQlSw |
| CitedBy_id | crossref_primary_10_3390_ijms252312809 |
| Cites_doi | 10.1053/j.gastro.2010.09.038 10.1007/s00535-013-0758-5 10.1053/jhep.2003.50346 10.1038/nrgastro.2017.109 10.1053/j.gastro.2019.01.042 10.1016/S0016-5085(99)70506-8 10.1016/j.jhep.2008.08.011 10.1186/s12876-022-02430-7 10.1002/hep.21178 10.1016/j.cgh.2018.04.043 10.14309/ajg.000000000000105433284184 10.1016/S2468-1253(19)30383-8 10.1111/apt.14327 10.1002/hep.24452 10.1016/j.metabol.2015.11.008 10.1111/j.1365-2036.2011.04722.x |
| ContentType | Journal Article |
| Copyright | The Author(s) 2024 2024. The Author(s). COPYRIGHT 2024 BioMed Central Ltd. 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2024 – notice: 2024. The Author(s). – notice: COPYRIGHT 2024 BioMed Central Ltd. – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7QR 7T5 7X7 7XB 88E 8FD 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FR3 FYUFA GHDGH H94 K9. M0S M1P P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12876-024-03295-8 |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts Chemoreception Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-230X |
| EndPage | 7 |
| ExternalDocumentID | oai_doaj_org_article_3ebcea8a79ba4e0ebae1e52d79b18bb9 PMC11229262 A800624536 38977950 10_1186_s12876_024_03295_8 |
| Genre | Journal Article |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: AHRQ HHS grantid: R01 HS026937 |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX ALIPV CITATION CGR CUY CVF ECM EIF NPM PMFND 3V. 7QP 7QR 7T5 7XB 8FD 8FK AZQEC DWQXO FR3 H94 K9. P64 PKEHL PQEST PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c608t-f05b72391cea40ef2876f9d1cf3f79076f6c3f8c113b30d295ae65db6c5ceffc3 |
| IEDL.DBID | M48 |
| ISSN | 1471-230X |
| IngestDate | Wed Aug 27 01:26:13 EDT 2025 Thu Aug 21 18:32:25 EDT 2025 Fri Sep 05 05:49:16 EDT 2025 Sat Jul 26 03:21:23 EDT 2025 Tue Jun 17 22:09:16 EDT 2025 Tue Jun 10 21:08:48 EDT 2025 Tue Jul 22 01:42:03 EDT 2025 Tue Jul 01 04:12:12 EDT 2025 Thu Apr 24 23:12:40 EDT 2025 Sat Sep 06 07:35:43 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Cirrhosis AGILE NHANES Advanced fibrosis MASLD Elastography |
| Language | English |
| License | 2024. The Author(s). Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c608t-f05b72391cea40ef2876f9d1cf3f79076f6c3f8c113b30d295ae65db6c5ceffc3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12876-024-03295-8 |
| PMID | 38977950 |
| PQID | 3079182911 |
| PQPubID | 44673 |
| PageCount | 7 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_3ebcea8a79ba4e0ebae1e52d79b18bb9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11229262 proquest_miscellaneous_3077176926 proquest_journals_3079182911 gale_infotracmisc_A800624536 gale_infotracacademiconefile_A800624536 pubmed_primary_38977950 crossref_primary_10_1186_s12876_024_03295_8 crossref_citationtrail_10_1186_s12876_024_03295_8 springer_journals_10_1186_s12876_024_03295_8 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-07-08 |
| PublicationDateYYYYMMDD | 2024-07-08 |
| PublicationDate_xml | – month: 07 year: 2024 text: 2024-07-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC gastroenterology |
| PublicationTitleAbbrev | BMC Gastroenterol |
| PublicationTitleAlternate | BMC Gastroenterol |
| PublicationYear | 2024 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | RJ Wong (3295_CR3) 2017; 46 CD Williams (3295_CR5) 2011; 140 N Alkhouri (3295_CR17) 2022; 22 C Matteoni (3295_CR4) 1999; 116 MS Siddiqui (3295_CR11) 2019; 17 CT Wai (3295_CR6) 2003; 38 RK Sterling (3295_CR8) 2006; 43 GT Brown (3295_CR2) 2016; 65 M YounossiZM, Noureddin (3295_CR13) 2021; 116 Y Kawano (3295_CR14) 2013; 48 3295_CR16 PJ Eddowes (3295_CR10) 2019; 156 P Nahon (3295_CR12) 2008; 49 FC Kruger (3295_CR7) 2011; 101 R Hernaez (3295_CR9) 2011; 54 3295_CR15 Z Younossi (3295_CR1) 2018; 15 |
| References_xml | – volume: 140 start-page: 124 year: 2011 ident: 3295_CR5 publication-title: Gastroenterology doi: 10.1053/j.gastro.2010.09.038 – volume: 48 start-page: 434 year: 2013 ident: 3295_CR14 publication-title: J Gastroenterol doi: 10.1007/s00535-013-0758-5 – volume: 38 start-page: 518 year: 2003 ident: 3295_CR6 publication-title: Hepatology doi: 10.1053/jhep.2003.50346 – volume: 15 start-page: 11 issue: 1 year: 2018 ident: 3295_CR1 publication-title: Nat Rev Gastroenterol Hepatol doi: 10.1038/nrgastro.2017.109 – volume: 156 start-page: 1717 issue: 6 year: 2019 ident: 3295_CR10 publication-title: Gastroenterology doi: 10.1053/j.gastro.2019.01.042 – volume: 116 start-page: 1413 year: 1999 ident: 3295_CR4 publication-title: Gastroenterology doi: 10.1016/S0016-5085(99)70506-8 – volume: 49 start-page: 1062 issue: 6 year: 2008 ident: 3295_CR12 publication-title: J Hepatol doi: 10.1016/j.jhep.2008.08.011 – volume: 22 start-page: 366 year: 2022 ident: 3295_CR17 publication-title: BMC Gastroenterol doi: 10.1186/s12876-022-02430-7 – volume: 43 start-page: 1317 year: 2006 ident: 3295_CR8 publication-title: Hepatology doi: 10.1002/hep.21178 – volume: 17 start-page: 156 issue: 1 year: 2019 ident: 3295_CR11 publication-title: Clin Gastroenterol Hepatol doi: 10.1016/j.cgh.2018.04.043 – volume: 116 start-page: 254 issue: 2 year: 2021 ident: 3295_CR13 publication-title: Am J Gastroenterol doi: 10.14309/ajg.000000000000105433284184 – ident: 3295_CR16 doi: 10.1016/S2468-1253(19)30383-8 – volume: 46 start-page: 974 year: 2017 ident: 3295_CR3 publication-title: Aliment Pharmacol Ther doi: 10.1111/apt.14327 – volume: 54 start-page: 1082 issue: 3 year: 2011 ident: 3295_CR9 publication-title: Hepatology doi: 10.1002/hep.24452 – volume: 65 start-page: 1080 year: 2016 ident: 3295_CR2 publication-title: Metabolism doi: 10.1016/j.metabol.2015.11.008 – volume: 101 start-page: 477 year: 2011 ident: 3295_CR7 publication-title: South Afr Med J – ident: 3295_CR15 doi: 10.1111/j.1365-2036.2011.04722.x |
| SSID | ssj0017823 |
| Score | 2.3884041 |
| Snippet | Background
Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value... Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value (PPV) which... Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value... BackgroundStudies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive predictive value... Abstract Background Studies attempted to estimate MASLD-related advanced fibrosis (AF) and cirrhosis (MC) prevalence utilized tests with low positive... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 218 |
| SubjectTerms | Adult Advanced fibrosis AGILE Biopsy Body mass index Care and treatment Cirrhosis Diagnosis Disease control Distribution Elastography Fatty Liver - complications Fatty Liver - epidemiology Female Fibrosis Gastroenterology Gender Hemoglobin Hepatitis B Hepatology Humans Internal Medicine Liver cirrhosis Liver Cirrhosis - epidemiology Liver diseases Male MASLD Medicine Medicine & Public Health Metabolic diseases Metabolism Middle Aged NHANES Nutrition Surveys Obesity Population Predictive Value of Tests Prevalence Severity of Illness Index United States - epidemiology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQD4gL4p-FggYJCVCJmsSJ43BbYMuC2r2USr1ZsWOrkZbsarM9lFOvnHnDvgCvwIyTLE0RcOGwWSVxLNvzeX7k8WfGnueJ4TLTIigkt0GCEUQgLV60STS64wUtbVG2xUxMj5JPx-nxpaO-KCespQduB26XW21sIYss10ViQ6sLG9k0LvE-klr7rXto8_pgqls_QLvH-y0yUuw2qIUzSrZNgpDHeRrIgRnybP2_6-RLRulqwuSVVVNvjPZusZudFwnjtvW32TVb32HXD7p18rvsB0ofliui8qaZCwsHX-wa5T2vDJRnDVkzkkhQdNKxJZC41wusEOaUqwHd0g28PBgf7r9_FfhdL1iuzxoAh5H2oqkaKOoSTLVanfi7qgZ0KqF1ZqF1ZmG5OScMEOnz6it2C8YfPu5PgF-cf9vBH9XSPkmgIXLN5g3W3FKmUAeo0tl0PJscAroT2cX5d_yTYM5wBO6xo73J53fToDvaITAilOvAhanOYp5HKNsktI7E4_IyMo67DON14YThTpoo4pqHJYqssCIttTCpsc4Zfp9t1YvaPmTgQhMjMExOB5pbbgtnpbCizDP0Zg0PRyzqJa1Mx3tOx2_MlY9_pFAtOhSiQ3l0KDliO5tvli3rx19LvyUAbUoSY7d_gDhWHY7Vv3A8Yi8Ifor0CjbPFN32COwkMXSpsaTtrknKxYhtD0qiPjDD1z2AVaePGoWaPMdIEi3biD3bvKYvKceutotTXwZje5HHWMWDFu-bLqFbm2V5ioMpBzNh0Ofhm7o68Wzl6NDHREo5Yq_7SfOrXX8e1Ef_Y1Afsxuxn_RZEMpttrVendon6ESu9VOvL34C91Ny_g priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LbtQw0IKthLgg3gQKMhISoBI1iRPH4YK2sKWgdoUolXqzYsemkZZk2WwP5dQrZ_6wP8AvMJM4KVtED5tV4onl8Tw8zoxnCHmWxZqJVHE_F8z4MewgfGHgonSswBzP0bWF0RZTvnMQfzxMDt0Ht8aFVfY6sVXURa3xG_km8GIGtjDI5pv5dx-rRqF31ZXQuErWQAWLZETWtibTT58HPwKsf6w_KiP4ZgNAKQbdxn7Aoizxxcpy1Gbt_1c3_7U4XQycvOA9bRel7ZvkhrMm6bgj_y1yxVS3ybU95y-_Q34DF9D5AlN6owTT2tJvZgl0n5WaFicNrmpIGT93VDIFRbIva-iQzjBmgzoXDn2xN97ffffSb0-_AFwfPUAt7LjrpmxoXhVUl4vFUXtXVhSMS9oZtbQzaul8qBdGgeNn5Q9Ai47ff9idUHZ2-nMDfthL9ySmDSbZbF5Dz13qFEQAO53ujKeTfQpmRXp2-gv-BNUnMAN3ycH25MvbHd-VePA1D8TSt0Gi0ohloTZ5HBiL5LFZEWrLbAr7dm65ZlboMGSKBQWQLDc8KRTXiTbWanaPjKq6Mg8ItYGOYhPoDAubG2ZyawQ3vMhSsGo1CzwS9pSW2uU_xzIcM9nugwSXHXdI4A7ZcocUHtkY3pl32T8uhd5CBhogMXN3-6BefJVOEUhmFOAq8jRTOQzXqNyEJokKuA-FUplHniP7SdQvMDydu2MSgCRm6pJjgcde44Rxj6yvQIJe0KvNPQNLp5caeS5FHnk6NOObGGtXmfq4hYE9Ps8i6OJ-x-8DSmDepmmWwGSKFUlYwXm1pSqP2qzlYNhHmJzSI696oTkf1_8n9eHlaDwi16NWnFM_EOtktFwcm8dgJi7VE6cL_gCIJWmP priority: 102 providerName: ProQuest – databaseName: Springer Nature OA Free Journals dbid: C6C link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtQw0IIiIS6IN2kLGiQkQCUiiRPH4baULQtq91Iq9WbFjq1GWrKrzfZQTr1y5g_7A_wCM0k2NOUhcdisEo8tj2c8D814zNjzLDZcplr4ueTWj9GD8KXFhzaxRnM8p9AWZVtMxeQo_nScHHdlcugszOX4fSjFmxrlZ0ppsrEf8ChLfHmd3UiozhgFZsVuHzFATcfXh2L-2G-geJr6_L9L4Utq6GqK5JU4aaN-9u6w253dCKOW0HfZNVvdYzcPusj4ffYD6Q2LJRXvpr0Kcwdf7AopPCsNFGc16S-igZ939LAFEIFXcxwQZpSdAV2wBl4ejA7337_ym3MuCLfOEwCHvvW8LmvIqwJMuVyeNG9lBWhGQmu-Qmu-wqK_GQyQt2flV0QLRh8-7o-BX5x_28EfjdJ-iaGmcpr1Wxy5LZJCCNCg08loOj4ENCDSi_Pv-CfBnOEKPGBHe-PPuxO_u8zBNyKQK98FiU4jnoXG5nFgHZHHZUVoHHcpeujCCcOdNGHINQ8KJFluRVJoYRJjnTP8Iduo5pV9zMAFJoptYDK6wtxymzsrhRVFlqL9anjgsXBNaWW6Sud04cZMNR6PFKrlDoXcoRruUNJjO32fRVvn45_Q74iBekiq0d18QNZV3ZZX3GrEVeZppnOcrtW5DW0SFfgeSq0zj70g9lMkSXB6Ju8ORCCSVJNLjSQdcI0TLjy2PYBECWCGzWsGVp0EqhXK7gx9R9RlHnvWN1NPyqqr7Py0gUFvXmQRDvGo5fceJTRk0zRLcDHlYCcMcB62VOVJU58cTfiIylB67PV60_ya198XdfP_wLfYrajZ3qkfyG22sVqe2idoIK7000Yy_ATyu2Ej priority: 102 providerName: Springer Nature |
| Title | The prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD)-related advanced fibrosis and cirrhosis in the United States population utilizing AGILE 3 + and AGILE 4 scores: analysis of the NHANES 2017–2018 cycle |
| URI | https://link.springer.com/article/10.1186/s12876-024-03295-8 https://www.ncbi.nlm.nih.gov/pubmed/38977950 https://www.proquest.com/docview/3079182911 https://www.proquest.com/docview/3077176926 https://pubmed.ncbi.nlm.nih.gov/PMC11229262 https://doaj.org/article/3ebcea8a79ba4e0ebae1e52d79b18bb9 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3bbtMw1NpFmvaCuBMYlZGQAI2MJE4cBwmhtnQUtFZoo1LFS5Q4NqtU0tJ0EuVprzzzh_sBfoFznKRbx-CBh6ZyfKmPfa718TmEPI58yUSYcjsRTNk-WBC2UPBIpZ-COp7g0RZ6W_R5d-C_HwbDNVKnO6oWsLjStMN8UoPZeO_b18VrIPhXhuAFf1EAjw3Rlda3HeZFgS3WySZIJo5Y3vPPTxVAGrL64syV_bbJFgjwMIzwGv4FOWXC-f_JtC9IrcselZeOVY202r9OrlVqJm2WeHGDrKn8JtnqVQfpt8gvQA86nWGsbyRtOtH0i5oDQoxHkmaLAsUdbpmdVNunMor4MJ_AgHSMzhy0OtuhT3vNo4M3z2xzLQba1W4FVIMpPilGBU3yjMrRbHZsSqOcgtZJS22XltounS4TiVEghfHoO4BFm2_fHXQoOzv9sQsfHKV849MCo28WL2HkMqYKAoCD9rvNfueIgr4Rnp3-hC9B5QJW4DYZ7Hc-trt2lfvBltwRc1s7QRp6LHKlSnxHadwpHWWu1EyHYNBzzSXTQrouS5mTwe4ligdZymUgldaS3SEb-SRX9wjVjvR85cgIM54rphKtBFc8i0JQdyVzLOLWOx3LKjA65ucYx8ZAEjwuESUGRIkNosTCIrvLPtMyLMg_W7cQgZYtMaS3eTGZfY4rDhEzlQKsIgmjNIHpqjRRrgq8DMquSNPIIk8Q_WIkBZieTKr7EwAkhvCKmwLvw_oB4xbZWWkJDEOuVtcIHNf0FgOrj8DUBNFnkUfLauyJTni5mpyYNmD888iDIe6W-L4EqSYbi4gVSliBebUmHx2bcOag8XsYtdIiz2uiOZ_X3xf1_v__0gOy7RmqD21H7JCN-exEPQTdcp42yHo4DBtks9XpfziEUpu3G-Z_moZhJfA8bH36DY7uflk |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGJgEviDuFAUYCARrWkjhxHCSEOtbRsa5Cu0h7M4ljs0olKU0nVJ72yjP_gx-1P8Bf4JxcOjrE3vbQVkmcIx_7O7faPoeQp5GvuQwTwWLJDfMhgmDSwFei_QTc8RiXtnC3RV909_0PB8HBAvnVnIXBbZWNTiwVdZpr_I98FbAYgS8Msvl29JVh1ShcXW1KaFSw2DLTbxCyFW8212F-n3neRmfvXZfVVQWYFo6cMOsESejxyNUm9h1jIWQQNkpdbbkNIVQUVmhupXZdnnAn9aIgNiJIE6EDbazVHOheIkvgZkQgRUtrnf7Hndm6Bdhb3hzNkWK1cJE6AzvIHA6UmJwzf2WVgH9twV_G8OxGzTOrtaUR3LhOrtXeK21XcLtBFkx2k1zertfnb5HfgDo6GmMKcdQYNLf0i5kAzoYDTdNpgVYUkcDiGhUmpQizSQ4E6RD3iNB6yYi-2G7v9tZfsvK0DbRrditQCxF-XgwKGmcp1YPx-LC8GmQUnFlaOdG0cqLpaFafjIKEDQffgS3afr_Z61B-cvxjBT5Ipbrj0wKTehavgXKVqgUZQKL9brvf2aXgxoQnxz_hR1I9hRG4TfYvZPLvkMUsz8w9Qq2jPd84OsJC6oab2BopjEijELxozZ0WcZuZVrrOt45lP4aqjLukUBU6FKBDlehQskVWZu-Mqmwj57ZeQwDNWmKm8PJGPv6sasWjuEmAVxmHURJDd00SG9cEXgrXrkySqEWeI_wU6jPono7rYxnAJGYGU22Jx2z9gIsWWZ5rCXpIzz9uAKxqPVioU6ltkSezx_gm7u3LTH5UtgndUEQekLhb4X3GErjTYRgFMJhyThLmeJ5_kg0OyyzpEEh4mAyzRV41QnPar_8P6v3z2XhMrnT3tnuqt9nfekCueqVoh8yRy2RxMj4yD8FFnSSPar1AyaeLVkV_AEO5p-I |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtNAcAWpVHFBvGsosEhIgIpV22uv19wMTUhDGiGVSr2tvOtdGik4UZweyqlXzvxhf4BfYMaPUJeHxCGO7H1oZ2d2HprHEvI8CTUTseJuJphxQ7AgXGHgoXSoQB3P0LWF0RYTPjwKR8fR8aUs_iravXVJ1jkNWKWpWO0uclsfccF3S-CqMQbPhq7HgiRyxXWyITioDz2ykaajw9HakwASkLXJMn8c2RFIVd3-37nzJfF0NXTyiv-0EkuDW-Rmo0_StCaA2-SaKe6QzYPGY36X_AA6oIslFvXGM0znln4xK8D8bKppflaiXEPcuFmDJ5NTRPxqDhPSGUZt0MaJQ18epIfjvVdulf8C_dr4AWrB5p6X05JmRU71dLk8qd6mBQX1ktZqLa3VWrpY3xhGgeZn068AFk3f74_7lF2cf9uBH85SfwlpiWU2yzcwc108BQHASSfDdNI_pKBYxBfn3-FPUH0GO3CPHA36n94N3eaSB1cDvlau9SIVByzxtclCz1hEj01yX1tmY7DcueWaWaF9nynm5YCyzPAoV1xH2lir2X3SK-aF2SLUejoIjacTvNrcMJNZI7jheRKDXquZ5xC_xbTUTQV0vIhjJitLSHBZU4cE6pAVdUjhkJ31mEVd_-Ofvd8iAa17Yu3u6sN8-Vk2rEAyowBWkcWJymC5RmXGN1GQw7svlEoc8gLJTyKHgeXprEmUACCxVpdMBSa-hhHjDtnu9ATOoLvNLQHLhjOVEnh6AjYlyDiHPFs340iMtivM_LTqA1Y-TwKY4kFN72uQQMGN4ySCzRSdk9CBudtSTE-quuWg2gdYntIhr9tD82tdf9_Uh__X_SnZ_Lg3kOP9yYdH5EZQnfTY9cQ26a2Wp-Yx6JAr9aRhEz8BfQVtvg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+prevalence+of+metabolic+dysfunction-associated+steatotic+liver+disease+%28MASLD%29-related+advanced+fibrosis+and+cirrhosis+in+the+United+States+population+utilizing+AGILE+3%E2%80%89%2B%E2%80%89and+AGILE+4+scores%3A+analysis+of+the+NHANES+2017%E2%80%932018+cycle&rft.jtitle=BMC+gastroenterology&rft.au=Alkhouri%2C+Naim&rft.au=Almomani%2C+Ashraf&rft.au=Le%2C+Phuc&rft.au=Payne%2C+Julia+Y.&rft.date=2024-07-08&rft.pub=BioMed+Central&rft.eissn=1471-230X&rft.volume=24&rft_id=info:doi/10.1186%2Fs12876-024-03295-8&rft_id=info%3Apmid%2F38977950&rft.externalDocID=PMC11229262 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-230X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-230X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-230X&client=summon |